-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Group Launches Training Program to Enhance Pharmaceutical Production Quality Management Capabilities
Category:
发布时间：2023-07-17
【概要描述】
To comprehensively enhance the enterprise’s pharmaceutical production quality management capabilities and support the Group’s high-quality development, Shijiazhuang Sihua Pharmaceutical Group has launched a 10-month training program on pharmaceutical production quality management since July 15.
To comprehensively enhance the enterprise’s pharmaceutical production quality management capabilities and support the Group’s high-quality development, Shijiazhuang Sihua Pharmaceutical Group has launched a 10-month training program on pharmaceutical production quality management since July 15.
“Over the 13 years since the implementation of the 2010 Edition of GMP, particularly as our enterprise continues to expand its production and business scale, we now undergo more than a dozen GMP compliance inspections each year. At the same time, we have consistently conducted in-depth training to enhance GMP management capabilities, ensuring that managers at all levels and the broader workforce promptly learn and master the latest requirements of quality regulations, continuously strengthen GMP awareness, and improve their self-assessment skills. This is an urgent imperative for the ongoing enhancement of our quality assurance capabilities and standards.” At the opening mobilization meeting for the training program, the General Manager of the Group’s Quality Technology Center stated that it is essential to continually elevate the level of quality management in pharmaceutical production, consistently ensure the manufacture of higher-quality medicines, and continuously meet the increasingly stringent demands of both the market and regulatory authorities. Moving forward, the company will further intensify quality management training efforts, foster a company-wide culture of continuous learning, cultivate and develop a pool of high-caliber talent, and enhance professional technical expertise and operational performance in quality management—thereby delivering high-quality products that better serve the market and support the Group’s innovative, high-quality development.
According to available information, this training program will span 10 months and will regularly engage senior industry-certified experts to deliver systematic instruction on GMP-related topics, including “Upholding the Quality Red Line and Building a Robust Quality Safeguard,” “Fully Implementing the ‘Four Strictest’ Quality Management Principles,” and other themes. The curriculum will cover, from a pharmaceutical manufacturing perspective, a comprehensive range of GMP knowledge—from understanding GMP principles and regulatory requirements to pharmacovigilance regulations and pharmaceutical risk management, as well as operational procedures and on-site management—aimed at comprehensively enhancing GMP regulatory awareness among managers at all levels and the broader workforce, deepening their understanding and interpretation of GMP provisions, and providing better guidance for production and business operations.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091